Last updated: February 19, 2026
What is the drug identified by NDC 60505-0223?
NDC 60505-0223 refers to Lasmiditan, a selective serotonin 5-HT1F receptor agonist approved for the acute treatment of migraine. Marketed under the brand name Reyvow by Eli Lilly, it was approved by the FDA in August 2019.
Market landscape overview
Prescription and Usage Data
- Launch date: August 2019.
- Indication: Acute migraine treatment.
- Market penetration: As of 2023, Lasmiditan has limited market share, primarily competing against triptans and CGRP inhibitors.
- Patient base: Estimated at 36 million migraine sufferers in the US, with roughly 20% refractory to standard therapies.
Competitor Analysis
| Drug Name |
Class |
Approval Year |
Market Share (2022) |
Price Range (per dose) |
Notable Features |
| Sumatriptan |
Triptan |
1992 |
35% |
$15-$20 |
Widely used, generic options available |
| Rizatriptan |
Triptan |
1998 |
10% |
$20-$25 |
Fast onset, widely prescribed |
| Ubrogepant |
CGRP receptor antagonist |
2019 |
8% |
$48-$65 |
Oral, rapid relief |
| Rimegepant |
CGRP receptor antagonist |
2020 |
12% |
$50-$70 |
Used for both acute and preventive treatment |
| Lasmiditan (Reyvow) |
5-HT1F receptor agonist |
2019 |
5% (est.) |
$32-$40 |
Non-vasoconstrictive, no cardiovascular contraindications |
Market Dynamics
- The market for migraine therapies remains competitive with new mechanisms gaining traction.
- Lasmiditan has a niche for patients unable to take vasoconstrictive triptans due to cardiovascular risk.
- Physician adoption remains gradual, constrained by limited familiarity and insurance reimbursement challenges.
Price analysis and projections
Current Pricing (2023)
| Parameter |
Details |
| Average wholesale price (AWP) |
$35-$40 per dose |
| Insurance reimbursement rate |
Typically 70%-80% of AWP |
| Out-of-pocket for patients |
$15-$25 per dose |
Cost Factors Influencing Pricing
- Manufacturing costs: Moderate due to complex synthesis.
- Market exclusivity: Patented until at least 2030, preventing generics.
- Pricing strategies: Premium pricing reflects the novel mechanism and target niche.
Price Projection (Next 3-5 years)
| Year |
Estimated Price Range (per dose) |
Notable Changes |
| 2024 |
$30-$40 |
Stable; insurance negotiations improve coverage |
| 2025 |
$28-$38 |
Competitive pressures increase, possible marginal decline |
| 2026 |
$25-$35 |
Potential entry of biosimilar or new entrants, though unlikely before patent expiry |
| 2027+ |
Stable to slight decline |
Long-term pricing influenced by payer negotiations |
Factors impacting future pricing
- Market penetration: Growth is expected but remains limited.
- Insurance coverage: Improved access can sustain price levels.
- Regulatory environment & patent protections: Maintain exclusivity until at least 2030.
- Potential biosimilars: Unlikely in the near term, given drug's chemical nature.
Key financial indicators
| Metric |
2022 Data |
Projections |
| Global sales estimate |
~$150 million |
$180-$250 million by 2026 |
| US market share |
4-5% |
7-10% with increased adoption |
| Average annual revenue per patient |
$150-$250 (based on usage patterns) |
Incremental growth with access expansion |
Regulatory and reimbursement landscape
- FDA approval: August 2019.
- Patent status: Valid till 2030; no generics expected before then.
- Reimbursement: Coverage by major insurers around 70%; negotiations could influence net prices.
Key Takeaways
- NDC 60505-0223 (Lasmiditan/Reyvow) holds a niche in the migraine therapeutics market targeting patients with contraindications to vasoconstrictors.
- Price per dose has stabilized around $35-$40, with potential for slight reduction due to market dynamics.
- Long-term sales growth depends on increased adoption, insurance coverage, and eventual biosimilar entry post-patent expiry.
- Competition from well-established triptans and emerging CGRP inhibitors constrains rapid market expansion.
FAQs
Q1: What factors limit the market share of Lasmiditan?
A: Physician familiarity, insurance coverage challenges, and competition from established therapies limit its adoption.
Q2: How does the price of Lasmiditan compare to triptans?
A: Lasmiditan's per-dose price ranges from $32 to $40, comparable or slightly higher than some branded triptans ($15-$25), but less than newer CGRP antagonists ($50-$70).
Q3: When might generic versions of Lasmiditan enter the market?
A: Post-2030, contingent upon patent expiry and regulatory approval.
Q4: What future market trends could impact the drug’s pricing?
A: Increased physician adoption, expanded insurance reimbursement, and biosimilar competition.
Q5: Are there any upcoming regulatory or clinical developments affecting this drug?
A: No announced regulatory actions; ongoing real-world evidence collection may influence future positioning.
References
[1] U.S. Food and Drug Administration. (2019). FDA approves new drug to treat migraine.
[2] IQVIA. (2022). Prescription drug market analysis.
[3] EvaluatePharma. (2023). Global sales forecast for migraine treatments.
[4] FDA Orange Book. (2023). Patent and exclusivity status of Lasmiditan.
[5] Walgreens. (2023). Drug pricing overview.
Note: Data and projections are based on available public sources up to 2023 and industry insights. Market conditions may evolve.
